Vir Biotechnology (VIR) Net Margin (2018 - 2026)
Vir Biotechnology (VIR) posted Net Margin of 433431.03% for Q1 2026, down 646870.77% sequentially from 66.99% in Q4 2025, and down 42944142.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Vir Biotechnology (VIR) Net Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Net Margin for 9 years, with the latest figure at 433431.03% in Q1 2026.
- Quarterly Net Margin fell 42944142.0% year-over-year to 433431.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 675.36% (up 209368.0% YoY) and the FY2025 annual result came in at 638.87%, up 6453.0% from the prior year.
- Net Margin slipped to 433431.03% in Q1 2026 per VIR's latest filing, from 66.99% in the prior quarter.
- Over five years, Net Margin peaked at 46.81% in Q3 2022 and troughed at 433431.03% in Q1 2026.
- A 5-year average of 31858.58% and a median of 845.23% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2026: Net Margin soared 859021 bps in 2022, then tumbled 42944142 bps in 2026.
- Over 5 years, Net Margin stood at 205.63% in 2022, then plunged by 236 bps to 690.85% in 2023, then retreated by 22 bps to 845.23% in 2024, then soared by 92 bps to 66.99% in 2025, then tumbled by 646871 bps to 433431.03% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 433431.03%, 66.99%, and 67975.42% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Vir Biotechnology | 1.92 Bn | 1.92 Bn | 238.95 Mn | 33.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.51% |
| Mar 31, 2026 | -433,431.03% |
| Dec 31, 2025 | -66.99% |
| Sep 30, 2025 | -67,975.42% |
| Jun 30, 2025 | -9,139.87% |
| Mar 31, 2025 | -3,989.61% |
| Dec 31, 2024 | -845.23% |
| Sep 30, 2024 | -8,979.71% |
| Jun 30, 2024 | -4,500.10% |
| Mar 31, 2024 | -115.79% |
| Dec 31, 2023 | -690.85% |
| Sep 30, 2023 | -6,192.23% |
| Jun 30, 2023 | -5,129.71% |
| Mar 31, 2023 | -223.80% |
| Dec 31, 2022 | -205.63% |
| Sep 30, 2022 | 46.81% |
| Jun 30, 2022 | -188.27% |
| Mar 31, 2022 | 42.08% |
| Dec 31, 2021 | 64.63% |
| Sep 30, 2021 | 106.57% |